Allogene Therapeutics (ALLO) Accumulated Expenses (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Accumulated Expenses data on file, last reported at $23.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 6.28% year-over-year to $23.4 million; the trailing twelve-month figure through Mar 2026 stood at $23.4 million (down 6.28% YoY), and the FY2025 full-year result was $28.2 million, down 6.26% from the prior year.
• Accumulated Expenses eased to $23.4 million in Q1 2026, from $28.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $44.6 million in Q1 2023 to a low of $23.4 million in Q1 2026.
• A 5-year average of $31.1 million and a median of $28.2 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 60.73% in 2023 and tumbled 44.94% in 2024, its largest moves.
• Tracing ALLO's Accumulated Expenses over 5 years: stood at $39.7 million in 2022, then dropped by 21.54% to $31.2 million in 2023, then retreated by 3.38% to $30.1 million in 2024, then retreated by 6.26% to $28.2 million in 2025, then retreated by 17.16% to $23.4 million in 2026.
• Business Quant data shows ALLO's Accumulated Expenses at $23.4 million in Q1 2026, $28.2 million in Q4 2025, and $28.1 million in Q3 2025.